|
PT3243526T
(pt)
|
2010-07-06 |
2020-03-04 |
Glaxosmithkline Biologicals Sa |
Distribuição de arn para despoletar múltiplas vias imunitárias
|
|
US10487332B2
(en)
|
2010-07-06 |
2019-11-26 |
Glaxosmithkline Biologicals Sa |
Immunisation of large mammals with low doses of RNA
|
|
CN103153284B
(zh)
|
2010-07-06 |
2015-11-25 |
诺华股份有限公司 |
含有其pKa值有利于RNA递送的脂质的脂质体
|
|
FI4005592T3
(fi)
|
2010-07-06 |
2023-01-13 |
|
Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
|
|
CA2804591C
(en)
|
2010-07-06 |
2019-01-22 |
Novartis Ag |
Cationic oil-in-water emulsions
|
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RS63890B1
(sr)
*
|
2010-08-31 |
2023-02-28 |
Glaxosmithkline Biologicals Sa |
Mali lipozomi za isporuku rnk koja kodira imunogen
|
|
JP5911870B2
(ja)
|
2010-08-31 |
2016-04-27 |
ノバルティス アーゲー |
免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
|
|
EP2857499A1
(en)
|
2010-10-01 |
2015-04-08 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
KR102266691B1
(ko)
*
|
2010-10-11 |
2021-06-23 |
노파르티스 아게 |
항원 전달 플랫폼
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
EP4074693A1
(en)
|
2011-06-08 |
2022-10-19 |
Translate Bio, Inc. |
Cleavable lipids
|
|
KR20220025112A
(ko)
|
2011-06-08 |
2022-03-03 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
|
JP2014522842A
(ja)
|
2011-07-06 |
2014-09-08 |
ノバルティス アーゲー |
免疫原性組み合わせ組成物およびその使用
|
|
US9655845B2
(en)
|
2011-07-06 |
2017-05-23 |
Glaxosmithkline Biologicals, S.A. |
Oil-in-water emulsions that contain nucleic acids
|
|
RU2014104090A
(ru)
*
|
2011-07-06 |
2015-08-20 |
Новартис Аг |
Липосомы с эффективным соотношением n:p для доставки молекул phk
|
|
US9636410B2
(en)
|
2011-07-06 |
2017-05-02 |
Glaxosmithkline Biologicals Sa |
Cationic oil-in-water emulsions
|
|
PT2750707T
(pt)
|
2011-08-31 |
2019-01-23 |
Glaxosmithkline Biologicals Sa |
Lipossomas peguilados para distribuição de arn que codifica imunogénio
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
PT3682905T
(pt)
|
2011-10-03 |
2022-04-07 |
Modernatx Inc |
Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
|
|
BR112014008694A2
(pt)
*
|
2011-10-11 |
2017-06-20 |
Novartis Ag |
moléculas de ácido nucleico policistrônico recombinante
|
|
ES2923757T3
(es)
|
2011-12-16 |
2022-09-30 |
Modernatx Inc |
Composiciones de ARNm modificado
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
CN104411338A
(zh)
|
2012-04-02 |
2015-03-11 |
现代治疗公司 |
用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
EA201492055A1
(ru)
|
2012-06-08 |
2015-11-30 |
Шир Хьюман Дженетик Терапис, Инк. |
ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
|
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
|
AU2014204826A1
(en)
|
2013-01-10 |
2015-07-09 |
Seqirus UK Limited |
Influenza virus immunogenic compositions and uses thereof
|
|
EP3434774A1
(en)
|
2013-01-17 |
2019-01-30 |
ModernaTX, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
PL2970948T3
(pl)
|
2013-03-15 |
2019-06-28 |
Glaxosmithkline Biologicals Sa |
Sposoby oczyszczania rna
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
PL3019619T3
(pl)
|
2013-07-11 |
2022-01-10 |
Modernatx, Inc. |
Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
|
|
CA2923029A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
WO2015126477A1
(en)
*
|
2013-11-08 |
2015-08-27 |
Tyrx, Inc. |
Polymeric drug delivery system for treating surgical complications
|
|
US10842859B2
(en)
*
|
2014-03-25 |
2020-11-24 |
Yale University |
Uses of parasite macrophage migration inhibitory factors
|
|
HRP20220070T1
(hr)
|
2014-04-23 |
2022-04-01 |
Modernatx, Inc. |
Cjepiva nukleinske kiseline
|
|
EP2974739A1
(en)
|
2014-07-15 |
2016-01-20 |
Novartis AG |
RSVF trimerization domains
|
|
EP3154576A1
(en)
|
2014-06-13 |
2017-04-19 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic combinations
|
|
WO2016011226A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3171895A1
(en)
|
2014-07-23 |
2017-05-31 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
|
EP3061826A1
(en)
|
2015-02-27 |
2016-08-31 |
Novartis AG |
Flavivirus replicons
|
|
AU2016251687C1
(en)
|
2015-04-22 |
2023-07-27 |
CureVac SE |
RNA containing composition for treatment of tumor diseases
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
HRP20220156T1
(hr)
|
2015-09-17 |
2022-04-15 |
Modernatx, Inc. |
Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
|
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
US20180271970A1
(en)
*
|
2015-10-22 |
2018-09-27 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
EP3364981A4
(en)
*
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
|
MA45209A
(fr)
|
2015-10-22 |
2019-04-17 |
Modernatx Inc |
Vaccins contre les maladies sexuellement transmissibles
|
|
PE20181531A1
(es)
*
|
2015-10-22 |
2018-09-26 |
Modernatx Inc |
Vacuna del virus herpes simple
|
|
SG11201803360UA
(en)
*
|
2015-10-22 |
2018-05-30 |
Modernatx Inc |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
|
MA46023A
(fr)
*
|
2015-10-22 |
2019-07-03 |
Modernatx Inc |
Vaccin contre le virus de la grippe à large spectre
|
|
CN108368028B
(zh)
|
2015-10-28 |
2021-09-03 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
DK3386484T3
(da)
|
2015-12-10 |
2022-07-04 |
Modernatx Inc |
Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
|
|
RS63051B1
(sr)
|
2015-12-22 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularnu isporuku agenasa
|
|
SMT202200310T1
(it)
|
2015-12-23 |
2022-09-14 |
Modernatx Inc |
Metodi di utilizzo dei polinucleotidi codificanti il ligando di ox40
|
|
US12678515B2
(en)
|
2015-12-30 |
2026-07-14 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
US20190241658A1
(en)
|
2016-01-10 |
2019-08-08 |
Modernatx, Inc. |
Therapeutic mRNAs encoding anti CTLA-4 antibodies
|
|
US10022436B2
(en)
|
2016-01-11 |
2018-07-17 |
Verndari, Inc. |
Microneedle compositions and methods of using same
|
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
WO2017208191A1
(en)
|
2016-06-02 |
2017-12-07 |
Glaxosmithkline Biologicals Sa |
Zika viral antigen constructs
|
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
EP3538067A1
(en)
|
2016-11-08 |
2019-09-18 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
MA46766A
(fr)
|
2016-11-11 |
2019-09-18 |
Modernatx Inc |
Vaccin antigrippal
|
|
EP3541416A1
(en)
|
2016-11-17 |
2019-09-25 |
GlaxoSmithKline Biologicals SA |
Zika viral antigen constructs
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
KR20240144261A
(ko)
|
2017-02-28 |
2024-10-02 |
사노피 |
치료적 rna
|
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
WO2018170256A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
KR102945203B1
(ko)
|
2017-05-08 |
2026-03-31 |
시애틀 프로젝트 코포레이션 |
알파바이러스 신생항원 벡터
|
|
EP4253544A3
(en)
|
2017-05-18 |
2023-12-20 |
ModernaTX, Inc. |
Modified messenger rna comprising functional rna elements
|
|
AU2018270111B2
(en)
|
2017-05-18 |
2022-07-14 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
|
|
PL3638776T3
(pl)
|
2017-06-14 |
2026-02-23 |
Technische Universität Dresden |
Sposoby i środki do zmiany genetycznej genomów z wykorzystaniem projektowanych enzymów rekombinujących dna
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3638292A1
(en)
|
2017-06-14 |
2020-04-22 |
ModernaTX, Inc. |
Polynucleotides encoding coagulation factor viii
|
|
MA49421A
(fr)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
Formulations d'arn
|
|
WO2019023566A1
(en)
*
|
2017-07-28 |
2019-01-31 |
Janssen Vaccines & Prevention B.V. |
METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP
|
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
MX2020002348A
(es)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Métodos de elaboración de nanopartículas lipídicas.
|
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
|
EP3461497A1
(en)
|
2017-09-27 |
2019-04-03 |
GlaxoSmithKline Biologicals S.A. |
Viral antigens
|
|
US11939601B2
(en)
|
2017-11-22 |
2024-03-26 |
Modernatx, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
|
JP7424976B2
(ja)
|
2017-11-22 |
2024-01-30 |
モダーナティエックス・インコーポレイテッド |
プロピオン酸血症の治療用のプロピオニルＣｏＡカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
|
|
EP3714048B1
(en)
|
2017-11-22 |
2025-04-09 |
ModernaTX, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
|
EA202091517A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
|
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
|
KR20200101394A
(ko)
|
2017-12-20 |
2020-08-27 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
엡스타인-바 바이러스 항원 구축물
|
|
KR20240134250A
(ko)
|
2018-01-04 |
2024-09-06 |
아이코닉 테라퓨틱스, 인코포레이티드 |
항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
|
|
US11802146B2
(en)
|
2018-01-05 |
2023-10-31 |
Modernatx, Inc. |
Polynucleotides encoding anti-chikungunya virus antibodies
|
|
US11911453B2
(en)
|
2018-01-29 |
2024-02-27 |
Modernatx, Inc. |
RSV RNA vaccines
|
|
CA3100050A1
(en)
|
2018-05-11 |
2019-11-14 |
Lupagen, Inc. |
Systems and methods for closed loop, real-time modifications of patient cells
|
|
MA52709A
(fr)
|
2018-05-23 |
2021-03-31 |
Modernatx Inc |
Administration d'adn
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
WO2020023390A1
(en)
|
2018-07-25 |
2020-01-30 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
|
AU2019321186B2
(en)
|
2018-08-17 |
2024-05-23 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions and uses thereof
|
|
MA53545A
(fr)
|
2018-09-02 |
2021-07-14 |
Modernatx Inc |
Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne
|
|
JP2022500436A
(ja)
|
2018-09-13 |
2022-01-04 |
モダーナティエックス・インコーポレイテッドModernaTX, Inc. |
糖原病を処置するためのグルコース−６−ホスファターゼをコードするポリヌクレオチド
|
|
US12644102B2
(en)
|
2018-09-13 |
2026-06-02 |
Modernatx, Inc. |
Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex E1-α, E1-β, and E2 subunits for the treatment of maple syrup urine disease
|
|
MA53615A
(fr)
|
2018-09-14 |
2021-07-21 |
Modernatx Inc |
Polynucléotides codant pour le polypeptide a1, de la famille de l'uridine diphosphate glycosyltransférase 1, pour le traitement du syndrome de crigler-najjar
|
|
CN112996854B
(zh)
|
2018-09-19 |
2024-08-30 |
摩登纳特斯有限公司 |
高纯度peg脂质和其用途
|
|
US12151029B2
(en)
|
2018-09-19 |
2024-11-26 |
Modernatx, Inc. |
PEG lipids and uses thereof
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
WO2020069169A1
(en)
|
2018-09-27 |
2020-04-02 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
|
KR20210090650A
(ko)
|
2018-11-07 |
2021-07-20 |
그릿스톤 바이오, 인코포레이티드 |
알파바이러스 신생항원 벡터 및 인터페론 억제제
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
CN113939282A
(zh)
|
2019-01-31 |
2022-01-14 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
DK3934673T3
(da)
*
|
2019-03-08 |
2026-04-07 |
Massachusetts Inst Technology |
Syntetisk onkolytisk lnp-replikon-rna og anvendelser til cancerimmunterapi
|
|
MA55321A
(fr)
|
2019-03-15 |
2022-01-19 |
Modernatx Inc |
Vaccins à base d'arn contre le vih
|
|
WO2020227642A1
(en)
|
2019-05-08 |
2020-11-12 |
Modernatx, Inc. |
Compositions for skin and wounds and methods of use thereof
|
|
SG11202113187WA
(en)
|
2019-05-30 |
2021-12-30 |
Gritstone Bio Inc |
Modified adenoviruses
|
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
|
CN114630675A
(zh)
|
2019-06-18 |
2022-06-14 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(hbv)疫苗和抗pd-1或抗pd-l1抗体的组合
|
|
EP3986915A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Recombinant interleukin 12 construct and uses thereof
|
|
CA3143634A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
|
JP2022536945A
(ja)
|
2019-06-18 |
2022-08-22 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ
|
|
EP3986563A1
(en)
|
2019-06-20 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
|
|
MX2022000879A
(es)
|
2019-07-21 |
2022-05-02 |
Glaxosmithkline Biologicals Sa |
Vacuna viral terapeutica.
|
|
AU2020351220A1
(en)
|
2019-09-19 |
2022-04-07 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4031524A1
(en)
|
2019-09-19 |
2022-07-27 |
ModernaTX, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4061405A1
(en)
|
2019-11-18 |
2022-09-28 |
Janssen Biotech, Inc. |
Vaccines based on mutant calr and jak2 and their uses
|
|
JP2023517644A
(ja)
|
2020-03-09 |
2023-04-26 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
コロナウイルスワクチン組成物及び方法
|
|
US12569553B2
(en)
|
2020-03-09 |
2026-03-10 |
Dynavax Technologies Corporation |
Shingles vaccines comprising a TLR9 agonist
|
|
US20230364219A1
(en)
|
2020-04-16 |
2023-11-16 |
Glaxosmithkline Biologicals Sa |
Sars cov-2 spike protein construct
|
|
IL298363A
(en)
*
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
AU2021285812A1
(en)
|
2020-06-01 |
2023-01-05 |
Modernatx, Inc. |
Phenylalanine hydroxylase variants and uses thereof
|
|
WO2021245611A1
(en)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
|
EP4171629A1
(en)
|
2020-06-29 |
2023-05-03 |
GlaxoSmithKline Biologicals S.A. |
Adjuvants
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
IL299571A
(en)
|
2020-07-08 |
2023-02-01 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
KR20230051172A
(ko)
|
2020-07-16 |
2023-04-17 |
아퀴타스 테라퓨틱스 인크. |
지질 나노 입자에 사용하기 위한 양이온성 지질
|
|
IL300026A
(en)
|
2020-08-06 |
2023-03-01 |
Gritstone Bio Inc |
Multiepitope vaccine cassettes
|
|
US12178921B2
(en)
|
2020-08-14 |
2024-12-31 |
Arcturus Therapeutics, Inc. |
Method of lyophilizing lipid nanoparticles
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
CA3199784A1
(en)
|
2020-11-13 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|
|
US20240299309A1
(en)
*
|
2020-12-22 |
2024-09-12 |
CureVac SE |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
US20240301006A1
(en)
|
2020-12-23 |
2024-09-12 |
Glaxosmithkline Biologicals Sa |
Self-amplifying messenger rna
|
|
AU2021412833A1
(en)
|
2020-12-28 |
2023-07-06 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
EP4032546A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Therapeutic viral vaccine
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
WO2022204380A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
|
WO2022204369A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
|
US20240207374A1
(en)
|
2021-03-24 |
2024-06-27 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
|
US20240189449A1
(en)
|
2021-03-24 |
2024-06-13 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
|
|
EP4313152A1
(en)
|
2021-03-26 |
2024-02-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
|
US20240285755A1
(en)
|
2021-05-24 |
2024-08-29 |
Glaxosmithkline Biologicals Sa |
Adjuvants
|
|
WO2022259191A1
(en)
|
2021-06-09 |
2022-12-15 |
Glaxosmithkline Biologicals Sa |
Release assay for determining potency of self-amplifying rna drug product and methods for using
|
|
US20240384277A1
(en)
|
2021-06-15 |
2024-11-21 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
|
US20240376445A1
(en)
|
2021-06-22 |
2024-11-14 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
US20240350410A1
(en)
|
2021-08-16 |
2024-10-24 |
Glaxosmithkline Biologicals Sa |
Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
|
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
US20250134824A1
(en)
|
2021-08-16 |
2025-05-01 |
Glaxosmithkline Biologicals Sa |
Low-dose lyophilized rna vaccines and methods for preparing and using the same
|
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
|
WO2023031855A1
(en)
|
2021-09-03 |
2023-03-09 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
|
US20250017867A1
(en)
|
2021-10-01 |
2025-01-16 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
|
CN115960922A
(zh)
*
|
2021-10-09 |
2023-04-14 |
吴可行 |
自复制rna分子设计及其应用
|
|
CA3232485A1
(en)
|
2021-11-15 |
2023-05-19 |
Technische Universitat Dresden |
Site-specific recombinases for efficient and specific genome editing
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023183909A2
(en)
|
2022-03-25 |
2023-09-28 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
|
WO2023198815A1
(en)
|
2022-04-14 |
2023-10-19 |
Janssen Vaccines & Prevention B.V. |
Sequential administration of adenoviruses
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
WO2023221938A1
(zh)
*
|
2022-05-16 |
2023-11-23 |
上海行深生物科技有限公司 |
蛋白包裹自复制rna及其制备方法
|
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
|
EP4562163A1
(en)
|
2022-07-26 |
2025-06-04 |
ModernaTX, Inc. |
Engineered polynucleotides for temporal control of expression
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
US12115217B2
(en)
|
2022-11-18 |
2024-10-15 |
Trustees Of Boston University |
Self-replicating RNA and uses thereof
|
|
WO2024133160A1
(en)
|
2022-12-19 |
2024-06-27 |
Glaxosmithkline Biologicals Sa |
Hepatitis b compositions
|
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
WO2024197033A1
(en)
|
2023-03-21 |
2024-09-26 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of heart failure
|
|
JP2026514719A
(ja)
|
2023-04-17 |
2026-05-13 |
テクニスチェ ユニベルシタト ドレスデン ケルパーシャフト デス エーフェントリッヒェン レヒツ |
部位特異的ｄｎａ組換えのための新規のリコンビナーゼ酵素
|
|
EP4701657A1
(en)
|
2023-04-27 |
2026-03-04 |
GlaxoSmithKline Biologicals S.A. |
Influenza virus vaccines
|
|
JP2026518411A
(ja)
|
2023-04-27 |
2026-06-08 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
インフルエンザウイルスワクチン
|
|
EP4704816A1
(en)
|
2023-05-03 |
2026-03-11 |
ModernaTX, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
|
EP4480490A1
(en)
|
2023-06-23 |
2024-12-25 |
Medizinische Hochschule Hannover |
Brick1 for use in treating myocardial diseases
|
|
CN121532514A
(zh)
|
2023-07-07 |
2026-02-13 |
上海环码生物医药有限公司 |
用于季节性流感的环状rna疫苗及使用方法
|
|
CN116726036B
(zh)
*
|
2023-07-27 |
2025-12-26 |
中国水产科学研究院黑龙江水产研究所 |
Nm107在抗传染性胰脏坏死病毒中的应用
|
|
EP4771042A1
(en)
|
2023-08-29 |
2026-07-08 |
Shanghai Circode Biomed Co., Ltd |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025043547A1
(zh)
|
2023-08-30 |
2025-03-06 |
杭州高田生物医药有限公司 |
T细胞导向免疫脂质体及其用途
|
|
IL326816A
(en)
|
2023-09-01 |
2026-04-01 |
Seamless Therapeutics Gmbh |
Method for the production of a target-specific large serine recombinase
|
|
WO2025072482A1
(en)
|
2023-09-27 |
2025-04-03 |
Modernatx, Inc. |
Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
|
|
AU2024363742A1
(en)
|
2023-10-16 |
2026-04-30 |
Technische Universität Dresden Körperschaft Des Öffentlichen Rechts |
Conditioned dna modifying enzyme comprising heterologous dna binding domain
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025229572A1
(en)
|
2024-05-01 |
2025-11-06 |
Glaxosmithkline Biologicals Sa |
Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines
|
|
WO2025255199A1
(en)
|
2024-06-05 |
2025-12-11 |
Modernatx, Inc. |
Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof
|
|
WO2025252950A1
(en)
|
2024-06-07 |
2025-12-11 |
Technische Universität Dresden Körperschaft Des Öffentlichen Rechts |
Method for producing spacer-specific dna recombining enzymes
|
|
US20260049306A1
(en)
|
2024-07-25 |
2026-02-19 |
Technische Universität Dresden Körperschaft Des Öffentlichen Rechts |
Modifying nucleic acid sequences having asymmetric target sites
|
|
CN120310792B
(zh)
*
|
2025-02-27 |
2026-01-30 |
复旦大学附属肿瘤医院 |
一种帽非依赖的线性mRNA表达系统及其应用
|
|
WO2026139456A2
(en)
|
2024-12-23 |
2026-07-02 |
Glaxosmithkline Biologicals Sa |
Self-amplifying messenger rna molecules
|